A PYMNTS Company

11th Cir. rejects FTC claim that AndroGel reverse payments protect monopoly profits

By  |  April 25, 2012

The U.S. Court of Appeals in Atlanta has rejected the FTC’s appeal of a district court ruling that granted pharmaceutical companies’ motion to dismiss. The FTC claimed that a pay for delay settlement between brand name and generic drug companies constituted an unlawful agreement not to compete in violation of Section 5(a) of the Federal Trade Commission Act.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The specific prescription drug at issue is AndroGel, developed by Besins and licensed by Solvay Pharmaceuticals. The generic manufacturers of AndroGel are Watson Pharmaceuticals and Paddock Laboratories. The FTC claimed that Solvay was unlikely to prevail on its infringement claims, and thus that the reverse payments protect monopoly profits.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    The court, however, stated the rule that “a reverse payment settlement is immune from antitrust attack so long as its anticompetitive effects fall within the scope of the exclusionary potential of the patent.” The fact that an infringement claim is likely to fail, as the FTC framed the argument, does not mean that the patent has no exclusionary potential.

    Full content: PDF of opinion

     

    Related content: 2025: Reverse-Payment Settlements Unleashed (Michael Carrier, Rutgers University School of Law)

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.